Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ascendiant Capital Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $12

Author: Benzinga Newsdesk | June 30, 2025 06:34am

Ascendiant Capital analyst Edward Woo initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price Target of $12.

Posted In: AYTU